Explanipedia

Correction: Asymmetric Dimethylarginine: A Never-Aging Story Open

Natalia Jarzebska, Stefan R. Bornstein, Sergey Tselmin, Ulrich Julius, Barbara Cellini , et al. · 2025

Asymmetric Dimethylarginine: A Never-Aging Story Open

Natalia Jarzebska, Stefan R. Bornstein, Sergey Tselmin, Ulrich Julius, Barbara Cellini , et al. · 2025

Human aging is intrinsically associated with the onset and the progression of several disease states causing significant disability and poor quality of life. Although such association was traditionally considered immutable, recent advances…

Neutrophil Extracellular Traps (NETs) as a Potential Target for Anti-Aging: Role of Therapeutic Apheresis Open

Natalia Jarzebska, Roman N. Rodionov, Karin Voit-Bak, Richard Straube, Anna Mücke , et al. · 2025

Neutrophil extracellular traps (NETs) are large structures composed of chromatin, histones and granule-derived proteins released extracellularly by neutrophils. They are generally considered to be a part of the antimicrobial defense strate…

The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report Open

Volker Schettler, N Selke, S Jenke, Thomas Zimmermann, Georg Schlieper , et al. · 2024

The current analysis of GLAR data indicates that regular LA leads to very low incidence rates of cardiovascular events in patients with high LDL-C and/or high Lp(a) levels, progressive ASCVD, and maximally tolerated lipid-lowering medicati…

Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis? Open

Ulrich Julius, Sergey Tselmin, В. А. Корнева · 2024

The article presents the up-to-date information on the effect of lipoprotein apheresis (LA) on atherosclerotic lesions. Some studies using modern diagnostic imaging techniques (such as intravascular ultrasound or magnetic resonance imaging…

Actual data on the apolipoprotein B part transported with lipoprotein(a) Open

Ulrich Julius · 2023

The German care high registry for familial hypercholesterolemia –Sex differences, treatment strategies, and target value attainment Open

F. Fath, Winfried März, Nina Schmidt, I. An Haak, Alexander Dressel , et al. · 2023

The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainment Open

Winfried März, Nina Schmidt, Ira an Haack, Alexander Dressel, Tanja B. Grammer , et al. · 2023

FH is under-treated in Germany compared to guideline recommendations. Male gender, genetic proof of FH, treatment by a specialist, and presence of ASCVD appear to be associated with increased treatment intensity. Achieving the LDL-C goals …

Erratum: State of the Art: Lipoproteinapherese Open

Ulrike Schatz, Volker Schettler, Ulrich Julius · 2023

Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study

State of the Art: Lipoproteinapherese Open

Ulrike Schatz, Volker Schettler, Ulrich Julius · 2023

Lipoprotein apheresis (LA) is usually a last resort in cardiovascular high-risk patients in the context of secondary prevention after lifestyle measures and maximal pharmacotherapy have failed to prevent the occurrence of new atherosclerot…

Repeated lipoprotein apheresis and immune response: Effects on different immune cell populations Open

Romy Walther, Rebekka Wehner, Antje Tunger, Ulrich Julius, Ulrike Schatz , et al. · 2022

Background Atherosclerosis is considered a chronic inflammation of arterial vessels with the involvement of several immune cells causing severe cardiovascular diseases. Lipoprotein apheresis (LA) improves cardiovascular conditions of patie…

The development of lipoprotein apheresis in Saxony in the last years Open

Solveig Kuss, Ulrike Schatz, Sergey Tselmin, Sabine Fischer, Ulrich Julius · 2022

Methods Three hundred thirty‐nine patients (230 men, 109 women) treated with lipoprotein apheresis in Saxony, Germany, in 2018 are described in terms of age, lipid pattern, risk factors, cardiovascular events, medication, and number of new…

Results of Therapy at a Lipid Clinic in Patients with Elevated Lipoprotein(a) levels Open

Ulrich Julius, Katarina Winter, Sergey Tselmin, Ulrike Schatz, Norbert Weiss , et al. · 2022

Aim: To describe the significance of additional atherogenic risk factors in patients with elevated lipoprotein(a) (Lp(a)) and the results of a treatment at a specialized outpatient clinic with respect to outcome data.

The Role of Cumulative LDL Cholesterol in Cardiovascular Disease Development in Patients with Familial Hypercholesterolemia Open

Victoria Korneva, Tatiana Kuznetsova, Ulrich Julius · 2022

In patients with familial hypercholesterolemia (FH) the exposure of very high LDL-C concentration and cumulative LDL-C level (cum LDL-C) can play a significant role in the prognosis. Objective: to analyze the contribution of “cum LDL-C for…

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases Open

Victoria Korneva, Tatjana Yurjevna Kuznetsova, Ulrich Julius · 2021

Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Traditional lipid-lowering therapy do…

Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events? Open

Ulrich Julius, Solveig Kuss, Sergey Tselmin, Ulrike Schatz, Stefan R. Bornstein · 2020

Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retr…

Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis Open

Reinhard Klingel, Franz Heigl, Volker Schettler, E. Roeseler, P. Grützmacher , et al. · 2019

Lipoprotein(a) (Lp(a)) consists of an LDL particle whose apolipoprotein B (apoB) is covalently bound to apolipoprotein(a) (apo[a]). An increased Lp(a) concentration is a causal, independent risk factor for atherosclerotic cardiovascular di…

Lipoprotein apheresis in Germany – Still more commonly indicated than implemented. How can patients in need access therapy? Open

Franz Heigl, Tobias Pflederer, Reinhard Klingel, R Hettich, Norbert Lotz , et al. · 2019

Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently…

Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results Open

Norbert Weiss, Ulrich Julius · 2019

Patients with symptomatic peripheral arterial disease (PAD) are at a very high risk of cardiovascular morbidity and mortality. Elevated lipoprotein(a) levels have been shown to be a risk factor for coronary artery disease (CAD) and stroke.…

Lipoprotein(a)—an interdisciplinary challenge Open

Ulrich Julius, S. Tselmin, Ulrike Schatz, Sabine Fischer, Stefan R. Bornstein · 2019

Lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor which is inherited and not changed by nutrition or physical activity. At present, only proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may mod…

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels Open

Volker Schettler, C. Neumann, Christian Peter, Thomas Zimmermann, Ulrich Julius , et al. · 2019

Lipoprotein(a) (Lp(a)) is a genetic risk factor for cardiovascular disease (CVD) and is associated with the induction and sustaining of atherosclerotic cardiovascular diseases (ASCVD). Since 2008 Lp(a) along with progressive CVD has been a…

Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors Open

Ulrich Julius, S. Tselmin, Ulrike Schatz, Sabine Fischer, Stefan R. Bornstein · 2019

Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably oth…

Real‐world study: Escalating targeted lipid‐lowering treatment with PCSK9‐inhibitors and lipoprotein apheresis Open

Ralf Spitthöver, Tilmann Röseler, Ulrich Julius, Franz Heigl, Volker Schettler , et al. · 2019

Introduction Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with monoclonal antibodies has complemented the armamentarium of lipid‐lowering therapy (LLT) before the final step of commencing chronic lipoprotein apheresis (…

NMR‐based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9‐inhibitor therapy (NAPALI‐Study) Open

Volker Schettler, Florian Muellendorff, Elke Schettler, C. Platzer, Sabine Norkauer , et al. · 2019

Taking into account the discordance between low‐density lipoprotein cholesterol (LDL‐C) and LDL particle (LDL‐P) number, cardiovascular risk more closely correlates with LDL‐P in patients. The aim of our study was to evaluate the number of…

Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry Open

Nina Schmidt, Alexander Dressel, Tanja B. Grammer, Ioanna Gouni‐Berthold, Ulrich Julius , et al. · 2018

LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW Open

Ulrich Julius, S. Tselmin, Stefan R. Bornstein · 2018

The first attempts to treat patients with homozygous familial hypercholesterolemia (HCH) were performed in the 60ies and 70ies using a total plasma exchange. Later on, more specific lipoprotein apheresis (LA) methods have been developed – …

P1703German lipoprotein apheresis registry-more than 5 years on Open

Volker Schettler, C. Neumann, Christian Peter, Thomas Zimmermann, Ulrich Julius , et al. · 2018

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients Open

Ulrich Julius · 2018

Lipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an extremely high risk of developing cardiovascular events (CVE), especially after all other therapeutic options were not tolerated, or appeared …

Commentary: Effects of different lipoprotein apheresis methods on serum protein levels Open

Ulrich Julius · 2018

Ulrich Julius YOU? Author Swipe